Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ccr.2010.04.028
Title: PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase
Authors: Wang, H.
Tan, C.P.
Guo, K.
Li, J.
Lim, S.G. 
Zeng, Q. 
Vardy, L.A.
Loo, J.M.
Zhou, J. 
Chng, W.J. 
Ng, S.B. 
Li, H.X.
Issue Date: 2010
Source: Wang, H., Tan, C.P., Guo, K., Li, J., Lim, S.G., Zeng, Q., Vardy, L.A., Loo, J.M., Zhou, J., Chng, W.J., Ng, S.B., Li, H.X. (2010). PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase. Cancer Cell 18 (1) : 52-62. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ccr.2010.04.028
Abstract: Overexpression of phosphatase of regenerating liver (PRL)-3 is associated with the progression of diverse human cancers. We show that the overexpression of PRL-3 protein is not directly associated with its transcript levels, indicating the existence of an underlying posttranscriptional regulation. The 5' untranslanted region (UTR) of PRL-3 mRNA possesses triple GCCCAG motifs capable of suppressing mRNA translation through interaction with PolyC-RNA-binding protein 1 (PCBP1), which retards PRL-3 mRNA transcript incorporation into polyribosomes. Overexpression of PCBP1 inhibits PRL-3 expression and inactivates AKT, whereas knockdown of PCBP1 causes upregulation of PRL-3 protein levels, activation of AKT, and promotion of tumorigenesis. An inverse correlation between protein levels of PRL-3 and PCBP1 in human primary cancers supports the clinical relevance. © 2010 Elsevier Inc.
Source Title: Cancer Cell
URI: http://scholarbank.nus.edu.sg/handle/10635/27100
ISSN: 15356108
DOI: 10.1016/j.ccr.2010.04.028
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

78
checked on Dec 6, 2017

WEB OF SCIENCETM
Citations

69
checked on Nov 17, 2017

Page view(s)

140
checked on Dec 10, 2017

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.